 |
18 Diseases |  |
22 Trials |
|
22 Trials |  |
2501 News |  |
| «12...10111213141516171819202122» |
- Sovaldi (sofosbuvir) / Gilead
IDENTIFICATION OF BASIC FACTORS OF BAD FORECAST RESPONSE TO SOFOSBUVIR / VELPATASVIR IN PATIENTS WITH HEPATITIS C TREATED IN REAL CLINICAL PRACTICE: RESULTS OF COHORTE HEPA-C () - Jan 27, 2020 - Abstract #AEEH2020AEEH_259;
- | Sovaldi (sofosbuvir) / Gilead
Journal: Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors. (Pubmed Central) - Jan 24, 2020
Interactions of EHCV subtypes 1, 2 and TDAV polymerases with sofosbuvir showed a similar molecular interaction pattern compared to HCV-NS5B, while interactions with dasabuvir were less conserved. In silico studies of molecular interactions between these modeled structures and sofosbuvir suggest that this compound could be efficient in combating equine pathogens, thus contributing to animal welfare.
- || imatinib / Generic mfg., Herceptin (trastuzumab) / Roche, Sovaldi (sofosbuvir) / Gilead
Clinical, Review, Journal: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib. (Pubmed Central) - Jan 21, 2020
The addition of SPC exclusivity has also heavily delayed competition and maintained high medicines prices in European countries. Ultimately, the granting of such extended exclusive private rights on medicines may result in unnecessary suffering and be a factor in the erosion of access to medicines for all.
- || Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. (Pubmed Central) - Jan 19, 2020
Hepatitis C virus (HCV) infection is considered as a major public health problem that, worldwide, chronically affects 170 million people. Due to progressive aging of the infected population, management of the elderly HCV-infected patients significantly emerged in the era of new therapies [1].
- | Sovaldi (sofosbuvir) / Gilead
Journal: Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents. (Pubmed Central) - Jan 17, 2020
To explore the application potential of dual prodrug strategies in the development of anti-HCV agents, a variety of sofosbuvir derivatives with modifications at the C4 or N3 position of the uracil moiety were designed and synthesized...Several active compounds were discovered, such as 25e (EC = 7.3 μM) and S-29b (EC = 19.5 μM). This kind of nucleosides were interesting and would open a new avenue for the development of antiviral agents.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. (Pubmed Central) - Jan 16, 2020
Despite its presence, most of identified baseline mutations did not negatively impact treatment outcome. Genetic diversity of circulating strains suggested that most of the Brazilian HCV chronic carriers are susceptible to new therapeutic regimens including recently approved DAAs.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. (Pubmed Central) - Jan 15, 2020
Although a virologic breakthrough occurred after an intermittent treatment regimen at the low fixed dose, the high fixed dose cured HCV-positive Huh7.5 cells with intermittent treatment. In conclusion, HCV is persistently present below detectable levels in HCV-infected Huh7.5 cells for a long time after treatment, and a shortened therapy duration is associated with an increased risk of virologic relapse, but virologic relapse or breakthrough might be avoided by treatment with a combination of more highly effective DAAs.
- velpatasvir (GS-5816) / Gilead, Sovaldi (sofosbuvir) / Gilead
Successful Allogenic and Autologous Transplant with Concurrent Usage of Direct-Acting Antivirals for Hepatitis C in Children with Hematological Malignancies. (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1322;
Use of DAAs is feasible during allogeneic and autologous SCT and does not interfere with mobilization or engraftment. This could decrease the risk of hepatic adverse events during SCT.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Identification and characterization of Zika virus NS5 RNA-dependent RNA polymerase inhibitors. (Pubmed Central) - Jan 11, 2020
Moreover, UA showed anti-ZIKV activity comparable to sofosbuvir. All these results indicate that UA is likely to be a promising lead compound against ZIKV, exhibiting a different mechanism than sofosbuvir.
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. (Pubmed Central) - Jan 8, 2020
All these results indicate that UA is likely to be a promising lead compound against ZIKV, exhibiting a different mechanism than sofosbuvir. Treatment of HCV patients coinfected with HIV using DAAs is associated with a rapid significant regression in hepatic fibrosis, as evaluated by FibroScan, FIB-4, and APRI scores.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy. (Pubmed Central) - Jan 2, 2020
P3b
In a randomized study of patients with chronic HCV genotype 1 infection who received previous treatment with sofosbuvir plus an NS5A inhibitor, 16 weeks treatment with G/P produced an SVR12 in more than 90% of patients, including those with compensated cirrhosis. ClinicalTrials.gov no: NCT03092375.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, Sovaldi (sofosbuvir) / Gilead
Journal: Translation of in vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. (Pubmed Central) - Jan 1, 2020
Outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates. SIGNIFICANCE STATEMENT: N/A.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C. (Pubmed Central) - Dec 29, 2019
Unexpectedly, patients with the CC genotype showed a dynamic increase in ISG expression between weeks 4 and 16 of DAA therapy, while the reverse was true for non-CC patients. These data provide an important dynamic link between host genotype and phenotype in HCV therapy also potentially relevant to naturally acquired infection.
- | Sovaldi (sofosbuvir) / Gilead
Trial completion date: Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (clinicaltrials.gov) - Dec 26, 2019
P4, N=10000, Completed, Sponsor: Tanta University
These data provide an important dynamic link between host genotype and phenotype in HCV therapy also potentially relevant to naturally acquired infection. Trial completion date: Mar 2018 --> Dec 2019
- | Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
Clinical, PK/PD data, Journal: Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. (Pubmed Central) - Dec 23, 2019
Dosing simulations shows that 400 mg sofosbuvir twice daily produce day 10 concentration range of 5.4 to 6.7 pmol/10 cells. The range of therapeutic values was identified for HCV patients receiving sofosbuvir in combination with ribavirin for 24 weeks, suggesting a potential pharmaceutical basis for individualized therapeutic dosing.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Electron diffraction determines molecular absolute configuration in a pharmaceutical nanocrystal. (Pubmed Central) - Dec 20, 2019
Data collection on multiple positions of a crystal and an advanced-intensity extraction procedure enabled us to solve the structure ab initio. We further show that dynamical diffraction effects are strong enough to permit unambiguous determination of the absolute structure of material composed of light scatterers.
- || Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report. (Pubmed Central) - Dec 20, 2019
However, this did not suffice to yield sustained viral clearance. Our well-characterized observation emphasizes the need for new treatment options to cure chronic hepatitis E in the setting of organ transplantation.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. (Pubmed Central) - Dec 19, 2019
Despite the reported highly dynamic subtype 4a of HCV; all the nucleotide inhibitors under the study are able to, tightly, bind to NS5b of genotype 4a. This behavior is reported before for the Zika virus polymerase, as well.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Trial initiation date: Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (clinicaltrials.gov) - Dec 18, 2019
P=N/A, N=60, Not yet recruiting, Sponsor: Kirby Institute
This behavior is reported before for the Zika virus polymerase, as well. Initiation date: Dec 2019 --> May 2020
- || yiqibuvir (HEC110114) / HEC Pharm
New P1/2 trial: The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (clinicaltrials.gov) - Dec 17, 2019
P1/2, N=24, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Effect of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with Oral antiviral therapy. () - Nov 24, 2019 - Abstract #APDW2019APDW_1408;
Twenty one patients with compensated HCV genotype 3-related cirrhosis with or without ascites and variceal bleed with Child pugh score B or C were given combination of sofosbuvir and daclatasvir without ribavarin for six months. Complete clinical response, variceal regression and regression of stiffness based on fibroscan following oral antivral therapy in compensated HCV cirrhosis is achievable, and may indicate regression of fibrosis and and decrease in portal pressure
- velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
A study on Treatment of Hepatitis C with Directly acting antivirals (DAA): Central India Experience. () - Nov 24, 2019 - Abstract #APDW2019APDW_1365;
Many studies in India have shown Genotype 3 as the commonest Genotype in India especially in North India. However, our study reveals predominance of Genotype 1 in central India and has shown excellent response in achieving SVR12 with DAA.
- Sovaldi (sofosbuvir) / Gilead
Absence of HCV RNA from the peripheral blood mononuclear cells is a predictor of good response after treatment of Egyptian Chronic hepatitis C patients with sofosbuvir based therapy (P4) - Nov 24, 2019 - Abstract #APDW2019APDW_666;
However, our study reveals predominance of Genotype 1 in central India and has shown excellent response in achieving SVR12 with DAA. Absence of HCV RNA in PBMCs is a better predictor of good response after treatment of CHC patients with DAAs, than its absence in the serum.
- velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Efficacy And Safety Of DAAs In HCV Infected, Treatment Naive patients, On Hemodialysis (P8) - Nov 24, 2019 - Abstract #APDW2019APDW_237;
The patients were treated with Sofosbuvir and another DAA for 12 weeks...Patients recieved three different DAA regimens (Sofosbovir (200 mg) + Daclatasvir (60 mg) N=12, Sofosbovir (400 mg) + Daclatasvir (60 mg) N=12 and Sofosbovir (400 mg) + Velpatasvir (100 mg) N=10)... DAAs are safe and effective in the treatment of Hepatitis C infection in chronic kidney disease patients on hemodialysis.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Are there any hurdles in the roadmap to HCV elimination by 2030?- An Observational study from a tertiary care centre in South India (P1) - Nov 24, 2019 - Abstract #APDW2019APDW_161;
The low SVR 12 attainment in genotype 3,especially treatment naive cirrhotics, poses a real hurdle in the roadmap to HCV elimination. Based on our study we put forward a solution that in this group,including CHILD A, ribavirin should be added to sofosbuvir + velpatasvir/daclatasvir for 12 weeks as mutational analysis is difficult in a resource limited country like India and newer drugs recommended are unavailable here.
- Sovaldi (sofosbuvir) / Gilead
The genotypic association of Hepatitis C associated Oral lichen planus and its response to direct acting antivirals (P1) - Nov 24, 2019 - Abstract #APDW2019APDW_57;
Eighteen patients with HCV-related OLP received Sofosbuvir with ribavirin for 24 weeks. HCV associated OLP responded to DDAs irrespective of the genotype corresponding to a reduction in escudier score.
- | Sovaldi (sofosbuvir) / Gilead
Journal: No need to discontinue hepatitis C virus therapy at the time of liver transplantation. (Pubmed Central) - Nov 21, 2019
HCV associated OLP responded to DDAs irrespective of the genotype corresponding to a reduction in escudier score. Interferon-free DAA therapy of HCV-infection given in the immediate pre- and post-operative LT period is safe, well-tolerated and yields high SVR rates.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Trial primary completion date: Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (clinicaltrials.gov) - Nov 20, 2019
P=N/A, N=60, Not yet recruiting, Sponsor: Kirby Institute
Interferon-free DAA therapy of HCV-infection given in the immediate pre- and post-operative LT period is safe, well-tolerated and yields high SVR rates. Trial primary completion date: Aug 2021 --> Dec 2021
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Trial initiation date: STRIVE-4: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (clinicaltrials.gov) - Nov 20, 2019
P4, N=30, Not yet recruiting, Sponsor: Kirby Institute
Trial primary completion date: Aug 2021 --> Dec 2021 Initiation date: Sep 2019 --> Nov 2020
- | Sovaldi (sofosbuvir) / Gilead
Journal: Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. (Pubmed Central) - Nov 19, 2019
The recent advent of direct acting antivirals (DAAs) in the therapeutic armamentarium of HCV infection made possible treatment of patients with advanced liver disease. Here we report on a rare association of a cirrhotic patient with HCV and Waldenström's Macroglobulinemia with severe cryoglobulinemia, who had already failed an interferon-based antiviral regimen, whose haematologic disease was ameliorated by HCV eradication following treatment with sofosbuvir and simeprevir with ribavirin, and where successful treatment was accompanied also by consistent improvement in liver function and parameters of portal hypertension.
- | Sovaldi (sofosbuvir) / Gilead
New P4 trial: The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy (clinicaltrials.gov) - Nov 18, 2019
P4, N=200, Enrolling by invitation, Sponsor: MTI University
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen. (Pubmed Central) - Nov 18, 2019
Conclusion HCV is highly prevalent in patients undergoing hemodialysis. Prompt treatment with SOF and DAC demonstrates a good response, with negligible side effects.
- emtricitabine/tenofovir disoproxil fumarate / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed? (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1880;
This reported discrepancy might be explained by considering (i) categorical but not continuous variables and (ii) HCV serostatus but not viral load in VACS index calculation. So, it needs to be modified to enhance its discrimination for post HCV cure changes.
- Daklinza (daclatasvir) / BMS, lamivudine / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Treatment with DAA HIV-HCV coinfected patient with XDR-tuberculosis (Sydney) - Nov 15, 2019 - Abstract #EACS2019EACS_1502;
ARV switched on ABC/3TC/LPVr in 2017...Sofosbuvir (SOF) 400mg and Daclatasvir (DCV) 60 mg initiated in August of 2017 for 12 weeks...Patient mentioned obvious improvement in physical functioning, vitality and bodily pain.Our clinical case indicate good tolerability and safety profile of the treatment with Sofosbuvir contain DAAs and drug interactions with Delamanid and Bedaquiline in difficult-to-treat cohort of HIV-HCV-coinfected patients with XDR-tuberculosis. Importantly, treatment of HCV-infection improve outcome of co-morbidities and general health.
- emtricitabine/tenofovir disoproxil fumarate / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed? (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1070;
This reported discrepancy might be explained by considering (i) categorical but not continuous variables and (ii) HCV serostatus but not viral load in VACS index calculation. So, it needs to be modified to enhance its discrimination for post HCV cure changes.
- emtricitabine/tenofovir disoproxil fumarate / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed? (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_605;
This reported discrepancy might be explained by considering (i) categorical but not continuous variables and (ii) HCV serostatus but not viral load in VACS index calculation. So, it needs to be modified to enhance its discrimination for post HCV cure changes.
- | Sovaldi (sofosbuvir) / Gilead
New trial: Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C (clinicaltrials.gov) - Nov 14, 2019
P, N=30, Active, not recruiting, Sponsor: Mohamed Saad
- |||| voxilaprevir (GS-9857) / Gilead, Sovaldi (sofosbuvir) / Gilead
Clinical: This was an informative case: Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation https://t.co/TZGlAsol8T (Twitter) - Nov 14, 2019
- | Sovaldi (sofosbuvir) / Gilead
Enrollment change, Trial withdrawal, Metastases: Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy (clinicaltrials.gov) - Nov 9, 2019
P=N/A, N=0, Withdrawn, Sponsor: Institute of Liver and Biliary Sciences, India
So, it needs to be modified to enhance its discrimination for post HCV cure changes. N=50 --> 0 | Recruiting --> Withdrawn
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study. (Pubmed Central) - Nov 8, 2019
N=50 --> 0 | Recruiting --> Withdrawn In this real-life study in a middle-income country, PWID treated for HCV and receiving a simple peer-support intervention demonstrated an excellent treatment response and good adherence, not associated with injecting drug use during treatment and OST at treatment initiation.
- ||||| Sovaldi (sofosbuvir) / Gilead
Clinical: #LiverMtg19 | Tomorrow, 8am-5pm, Hall B | Don’t miss Poster 0537 Course of Cirrhosis Regression: Lessons from Patients w/ #HCV #Cirrhosis Following Successful Sofosbuvir-Based Treatment @AASLDtweets @AMuir_DukeGI (Twitter) - Nov 7, 2019
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. (Pubmed Central) - Nov 2, 2019
In this real-life study in a middle-income country, PWID treated for HCV and receiving a simple peer-support intervention demonstrated an excellent treatment response and good adherence, not associated with injecting drug use during treatment and OST at treatment initiation. Sofosbuvir/Daclatasvir combined therapy could be a safe and effective treatment in adolescent patients 12 to 17 years old with chronic HCV genotype 4 infection.
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Hepatocellular carcinoma with a direct right atrial extension in an HCV patient previously treated with direct-acting antiviral therapy: a case report. (Pubmed Central) - Oct 30, 2019
Cardiac involvement in HCC rarely occurs and usually develops in advanced stages of HCC with very poor reported prognosis. Data regarding the relation between DAA and HCC development is controversial.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection. (Pubmed Central) - Oct 30, 2019
Treatment-emergent serious adverse events were experienced by two non-cirrhotic patients in each arm and no cirrhotic patient. Results demonstrate high efficacy and favorable tolerability of G/P in GT2-infected Japanese patients.
- | Cardilor (amiodarone) / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Journal: Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Bradycardiac Effects Caused by Co-Administration of Sofosbuvir and Amiodarone. (Pubmed Central) - Oct 29, 2019
This raised the possibility that the bradycardiac effects in vivo may originate in nodal cells, which have a more depolarized resting membrane potential compared with ventricular cells. The bradycardiac effects of sofosbuvir plus amiodarone in vitro are consistent with the clinical phenotype and suggest that our hiPSC-CMs may serve as a useful tool in assessing cardiac safety during drug discovery and development process.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE. (Pubmed Central) - Oct 27, 2019
P2
Globally, treatment was well tolerated. In conclusion, our findings support the concept of retreating with sofosbuvir+ grazoprevir/elbasvir + ribavirin for 16 weeks GT1 or GT4 DAA-experienced patients with proven NS5A or NS3 RAS.
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. (Pubmed Central) - Oct 27, 2019
Patients had to be DAA naïve, with the exception of sofosbuvir with/without IFN...The SVR12 rate in the RGT population was 97.2% (three relapses) whereas it was 98.8% (six relapses) in the control population (p = 0.382). Our findings suggest that testing for baseline NS5A-RASs in naïve HCV-infected patients does not enhance the rate of SVR to DAA-based IFN-free therapy in clinical practice.
- | voxilaprevir (GS-9857) / Gilead, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. (Pubmed Central) - Oct 26, 2019
In an analysis of data from 2 phase 3 clinical trials of patients with chronic HCV infection of any genotype, we found the combination of sofosbuvir, velpatasvir, with or without voxilaprevir, to increase PRO scores compared with placebo. These findings indicate the comprehensive benefit of these regimens during treatment and after SVR.
- Olysio (simeprevir) / J&J, Medivir, Sovaldi (sofosbuvir) / Gilead
Efficacy and Safety of Sofosbuvir Plus Simeprevir as Therapy for HCV-Associated Glomerulonephritis: Report of Two Cases () - Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5800;
Discussion This report describes two cases of HCV related Glomerulopathy with cryoglobulinemia treated with SOF plus SIM therapy showing no significant side effects and improvement hepatic and renal diseases. Clinical and Laboratory Characteristics of Patientes Before and After Treatment with Sofosbuvir plus Simeprevir
- Sovaldi (sofosbuvir) / Gilead
Experience with Directly Acting Antiviral Agents for Hepatitis C in Maintenance Hemodialysis Patients in a Single Center from Pakistan () - Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5348;
All the patients recieved sofosbuvir with one of the other available oral antiviral agents...Only 4 patients experienced Anemia, all recieving ribazole. Conclusion DAA based therapy delivered expected and desired results of therapy without any major therapy related adverse events in our center.